- Processing Solutions
- White Papers
- Buyer's Guide
WASHINGTON — U.S. Senator Charles E. Schumer announced Sunday that the Food and Drug Administration (FDA) has agreed to conduct a full review of the safety and legality of the new caffeine inhaler, AeroShot, which hit stores in New York and Boston this past month, WKBW.com reported.
The product, a lipstick sized disposable inhaler, allows the user to inhale a powder that sends 100mgs of caffeine into the body.
The product was introduced into New York and Boston markets in January without an age restriction on its purchase, without ever having been reviewed by the FDA and without having its safety claims independently verified by regulators.
In December, Schumer called on the FDA to review the safety and legality of the product – with a particular focus on both how it would affect teens and its use in combination with alcohol.
Sunday, Schumer announced that the FDA has agreed to his request and will conduct a review of the safety and legality of the product.
“A new product like AeroShot raises questions that need to be answered before allowing consumers, especially teens and kids, to use and abuse it,” said Schumer. “We need to make sure that AeroShot does not become the next Four Loko by facilitating dangerous levels of drinking among teenagers and college students.”